What Comes after Immuno-Oncology Therapy for Kidney Cancer?

Haris Zahoor*, Vinay Duddalwar, Anishka D'Souza, Axel S. Merseburger, David I. Quinn

*Corresponding author for this work
4 Citations (Scopus)

Abstract

The treatment landscape of advanced renal cell carcinoma (RCC) is rapidly evolving. Immune checkpoint inhibitors (ICI) have now become the preferred first line treatment with the approval of nivolumab and ipilimumab combination in intermediate to poor risk patients. Combination/s of ICI with vascular endothelial growth factor (VEGF) inhibitors will also be approved in future. The optimal treatment of patients who progress on ICI-based therapies is not well defined as of yet. In this review, we discuss the data regarding various treatment options available in this space, their limitations, and also provide our opinion regarding treatment selection.

Original languageEnglish
JournalKidney Cancer
Volume3
Issue number2
Pages (from-to)93-102
Number of pages10
ISSN2468-4562
DOIs
Publication statusPublished - 2019

Research Areas and Centers

  • Research Area: Luebeck Integrated Oncology Network (LION)
  • Centers: University Cancer Center Schleswig-Holstein (UCCSH)

DFG Research Classification Scheme

  • 205-14 Haematology, Oncology
  • 205-23 Reproductive Medicine, Urology

Cite this